Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Latest Action
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 is a legislative proposal introduced in the House during the 118th Congress. The bill aims to enhance federal efforts related to research, surveillance, prevention, and treatment of sickle cell disease and other heritable blood disorders. It was received in the Senate, read twice, and referred to the Committee on Health, Education, Labor, and Pensions. The bill ultimately failed or expired without becoming law. No official summary or full text is available in the provided data.
This bill sought to improve federal programs addressing sickle cell disease and similar blood disorders but did not advance beyond committee referral in the Senate and expired without enactment.
- The bill focuses on research, surveillance, prevention, and treatment of sickle cell disease and other heritable blood disorders.
- It was introduced in the House and later referred to the Senate Committee on Health, Education, Labor, and Pensions.
- The bill did not pass and is currently classified as failed or expired.
['Individuals affected by sickle cell disease and other heritable blood disorders', 'Federal health agencies involved in disease research and prevention', 'Healthcare providers and researchers specializing in blood disorders']
['The absence of detailed bill text and summary limits assessment of specific implementation mechanisms and funding requirements.', 'Potential challenges in coordinating surveillance and treatment programs across federal agencies and healthcare providers.', 'Oversight and authority provisions are unclear due to lack of full text, which may affect accountability.']
The bill was introduced in the House during the 118th Congress and referred to the Senate Committee on Health, Education, Labor, and Pensions. It did not advance to a vote or enactment and is currently classified as failed or expired. No further legislative actions or amendments are recorded in the provided data.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Improved federal research and surveillance could lead to better understanding and management of sickle cell disease and related disorders.', 'Enhanced prevention and treatment programs may reduce healthcare costs and improve quality of life for affected individuals.', 'Federal focus on these diseases might increase awareness and funding for related health initiatives.']
Due to the absence of the full bill text and official summary, transparency is limited, which restricts comprehensive oversight and public understanding of the bill's provisions and potential impacts. The bill's failure to advance beyond committee referral suggests limited legislative momentum during the 118th Congress.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.